论文部分内容阅读
目的分析冠心病合并糖尿病患者中用瑞舒伐他汀治疗的疗效及心血管事件发生的几率。方法选取2015年9月~2016年9月我院收治的冠心病合并糖尿病患者69例作为研究对象,将其进行分组,采用常规治疗的34例为对照组,另联合采用瑞舒伐他汀治疗的35例为研究组,对比两组治疗疗效。结果研究组治疗后血糖水平、血脂水平、心血管事件发生率及总有效率优于对照组,差异有统计学意义(P<0.05)。结论冠心病合并糖尿病患者中采用瑞舒伐他汀治疗,能有效降低心血管事件发生率,可推广。
Objective To analyze the curative effect and the incidence of cardiovascular events in patients with coronary heart disease and diabetes mellitus treated with rosuvastatin. Methods From September 2015 to September 2016, 69 patients with coronary heart disease and diabetes mellitus admitted to our hospital were selected as the research objects. The patients were divided into three groups: control group (34 cases) and rosuvastatin 35 cases for the study group, compared two groups curative effect. Results The blood glucose level, blood lipid level, the incidence of cardiovascular events and the total effective rate of the study group were better than those of the control group after treatment, the difference was statistically significant (P <0.05). Conclusion The use of rosuvastatin in patients with coronary heart disease and diabetes mellitus can effectively reduce the incidence of cardiovascular events and can be promoted.